ResMed Inc. stock (US7611521078): Shares firm after Q3 FY2026 revenue growth and valuation focus

ResMed Inc. shares on the NYSE are trading higher this week after the company reported double-digit revenue growth for Q3 FY2026, keeping investor attention on the U.S.-listed sleep and respiratory care specialist’s earnings momentum and valuation metrics.

ResMed Inc. shares in the United States have been in focus this week after the San Diego-based sleep and respiratory care specialist reported solid revenue growth for its third quarter of fiscal year 2026, keeping attention on the New York Stock Exchange-listed stock’s earnings momentum and valuation profile.

According to a recent analysis citing exchange pricing data, ResMed’s NYSE-listed shares (ticker: RMD) rose about 4.2% on 06/04/2026 to trade near USD 194.32, reflecting a rebound from earlier weakness in the stock over the past year.GuruFocus as of 06/04/2026

ResMed, which is headquartered in the United States and primarily listed on the NYSE, has also reported further progress in its core operations for the latest quarter, helping to underpin sentiment among investors focused on the U.S. healthcare and medical-technology space.

For its third quarter of fiscal 2026, the company announced that revenue reached about USD 1.4 billion, representing year-on-year growth of roughly 11% compared with the same period of the previous fiscal year, with the improvement driven mainly by demand for sleep and respiratory care devices and related offerings.Kalkine Media analysis referencing Q3 FY2026 results, published 05/2026

Alongside the top-line expansion, ResMed indicated that non-GAAP operating margins and profitability improved in Q3 FY2026, supported by higher volumes and an ongoing focus on cost management and product mix, according to the same analysis of the company’s quarterly update.Kalkine Media analysis referencing Q3 FY2026 results, published 05/2026

As of: 05.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: ResMed Inc.
• Sector/industry: Medical technology, sleep and respiratory care
• Headquarters/country: San Diego, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Sleep apnea devices, ventilators, masks and accessories, digital health solutions
• Home exchange/listing venue: New York Stock Exchange (RMD)
• Trading currency: USD

ResMed Inc.: core business model

ResMed focuses on developing and supplying medical devices and connected software that support the diagnosis, treatment, and long-term management of sleep-disordered breathing and chronic respiratory conditions, with revenue largely stemming from equipment sales and recurring consumables and cloud-based monitoring services.

Valuation metrics and multiples for ResMed Inc.

The recent price action around USD 194.32 per share on 06/04/2026 has brought renewed attention to how the market is valuing ResMed relative to its earnings power and long-term growth prospects, particularly among U.S. investors tracking healthcare and medical-technology companies.GuruFocus as of 06/04/2026

In that context, one valuation framework has compared the company’s trading price to an estimated intrinsic value, noting that ResMed’s shares were recently quoted at a level below a calculated fair-value estimate based on factors such as profitability, growth rates, and risk characteristics, underlining how valuation remains a central consideration for investors assessing the stock.GuruFocus as of 06/04/2026

Conclusion

ResMed’s latest quarter, marked by Q3 FY2026 revenue of around USD 1.4 billion and improved operating margins, has helped support the share-price recovery on the NYSE and reinforced the company’s position within the U.S. healthcare and medical-technology landscape.

At the same time, the recent trading level near USD 194.32 per share and the associated valuation discussion continue to frame how investors weigh the company’s earnings trajectory, competitive environment, and long-term growth drivers in sleep and respiratory care.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.